Developing a Proteomics Toolkit for the Characterization of Covalent Drug Molecules
- Pivoting away from mass spec in favor of building a high-throughput chemoproteomics hit identification platform
- Discovery of first-in-class inhibitors of a genetically validated target to treat PKU
- Discovery of the first inhibitors for transcription factor IRF3
- Evolving the platform to work with other covalent warheads